Bayer is a life science company with more than 150 years of experience and core competence in health and agriculture. In the area of pharmaceuticals, Bayer focuses on researching, developing and marketing specialty-focused innovative medicines that provide significant clinical benefit and value, primarily in the therapeutic areas of cardiology, oncology, gynecology, hematology and ophthalmology. The group has been operating in Sweden and Scandinavia for more than 70 years.
Contact
Address Berzelius väg 35
Solna, Sweden
Tel +46 8 580 223 00
Website https://www.bayer.se/
Tomer Feffer, Country Division Head Scandinavia & MD Bayer Sweden, shares his enthusiasm for Sweden’s innovative spirit and how Bayer is leveraging it through partnerships with medical technology and digital…
Ingo Brandenburg, managing director of Bayer Taiwan, brings over two decades of international pharmaceutical experience spanning Asia, Latin America, and Europe. With previous leadership roles, he has cultivated a deep…
The latest news from German pharma, including looming drug pricing reform, Boehringer Ingelheim’s EUR 640 million acquisition of a Kyowa Kirin autoimmune drug, and BioNTech’s updated revenue guidance. Also covered…
A summary of top stories from China’s pharma industry: Sciwind Biosciences presents promising trial data for its obesity contender; Simcere reaches approval for its Idorsia-partnered insomnia therapy; AstraZeneca inks AI-enabled…
A summary of some of the top stories coming out of Germany’s biopharma industry, including Bayer’s EMA win for its Eylea eye therapy; the oncology deal Merck KGaA has cut…
Saudi Arabia’s pharmaceutical sector continues its impressive growth leadership within the region. With a 9.1 percent market growth in 2024 and a projected USD 11.6 billion in sales, the Kingdom…
In 2024, global biopharma faced a challenging landscape shaped by geopolitical tensions and cost containment measures in key markets. Despite these pressures, most major players perhaps surprisingly opted to retain…
A roundup of the biggest stories coming out of Germany’s pharma industry, including Bayer’s biggest share price drop in 20 years; Fresenius Kabi’s biosimilar deal with SamChunDang Pharm; Halozyme Therapeutics’…
This interview explores Bayer’s strategic initiatives across the Middle East and North Africa (MENA) region, highlighting its commitment to innovation, local talent development, and sustainability. Over the next few years,…
An overview of some of the top stories from China’s pharma industry, including the arrest of AstraZeneca China’s top executive; Pfizer’s USD 1 billion China investment; WuXi AppTec’s continuing revenue…
The latest news from German pharma, including why Merck KGaA is looking to life science M&A; positive outlooks for Bayer and STADA; BioNTech’s move into the AI lab assistant space…
A roundup of some of the top stories coming out of China’s pharma industry, including AstraZeneca’s USD 1.92 billion deal with CSPC; Bayer’s new Shanghai incubator; Genentech’s purchase of Regor…
A roundup of some of the biggest stories coming out of German pharma, including Merck’s better-than-expected Q1 earnings; Stada’s possible return to the stock market; CDMO Vetter’s expanded capacity in…
See our Cookie Privacy Policy Here
